Injectable Pricing & Rebate Tracker: Botox, Dysport, Jeuveau, Daxxify, Xeomin

Neurotoxin pricing is quoted in units, not vials. A standard vial of Botox (100 units) costs roughly $10–$13 per unit at typical practice volumes, meaning $1,000–$1,300 per vial wholesale. Dysport (500 units per vial) runs $3–$5 per unit, or $1,500–$2,500 per vial—higher absolute cost but lower per-unit cost, which matters for high-volume practices. Jeuveau (100 units) typically prices at $8–$11 per unit to compete on cost. Daxxify (100 units) commands a premium—$12–$15 per unit—reflecting its longer duration claim (up to 6 months vs. 3–4 for others). Xeomin (100 units) sits at $9–$12 per unit. These ranges compress or expand based on your annual volume commitment, rebate tier, and whether you're buying direct or through a group purchasing organization (GPO). Verify current pricing with your manufacturer rep; these figures shift quarterly and vary by region and practice size.

Allē is AbbVie's loyalty program for Botox, Jeuveau, and dermal fillers (Volbella, Voluma, Vollure, Juvéderm family). The program operates on annual spend tiers: practices typically earn 2–5% rebates on Botox purchases, with higher rebates at $100K+, $250K+, and $500K+ annual spend thresholds. Rebates are paid quarterly or annually, not at point of sale. The catch: you must enroll, track spend, and reconcile invoices. Allē also offers co-marketing support and patient financing (Allē Pay) integration, which can drive volume but adds operational overhead. For a practice injecting 500 vials of Botox annually at $1,200/vial ($600K spend), a 3% rebate yields $18K back—meaningful, but only if you hit the tier. Practices often stack Allē with group purchasing agreements to lower baseline cost further. Check your Allē dashboard quarterly; many practices leave rebates unclaimed because they don't track or submit claims properly.

Aspire Rewards is Galderma's program covering Dysport, Restylane fillers (Contour, Lyft, Refyne, Defyne), and Radiesse. The structure is similar to Allē: tiered rebates (typically 2–4%) based on annual spend, paid in arrears. Dysport's lower per-unit cost makes it attractive for high-volume practices, and Aspire rebates can push effective per-unit cost below $3 at top tiers. Galderma also offers marketing co-op funds and preferred pricing on device purchases (e.g., Cutera or Cynosure equipment discounts). One advantage: Aspire integrates with some EMR systems, making spend tracking easier. Dysport's 500-unit vial means you're buying fewer vials per patient, which can reduce waste and simplify inventory. Practices using Dysport as a primary toxin often see better cash flow because they're buying fewer, larger vials. Confirm your Aspire tier annually; volume can shift, and you may qualify for a higher rebate without asking.

Evolus Rewards is Jeuveau's loyalty program, offering 3–6% rebates on Jeuveau purchases based on annual volume. Jeuveau is positioned as a lower-cost alternative to Botox, and Evolus uses Rewards to drive adoption and retention. The program is simpler than Allē or Aspire—fewer tiers, fewer compliance requirements—but the rebate pool is smaller because Jeuveau has a smaller market share. For practices using Jeuveau as a secondary toxin or for price-sensitive patients, Evolus Rewards can be attractive; the rebate structure is transparent and the company is responsive to practice feedback. However, Jeuveau's clinical adoption remains lower than Botox or Dysport, so patient demand may limit volume. Practices that commit to Jeuveau as a primary toxin can negotiate custom rebate rates directly with Evolus; the company is more flexible than larger competitors. Track Evolus Rewards separately from Allē and Aspire to avoid confusion.

A typical practice injects Botox at $12–$18 per unit retail (patient-facing price), with wholesale cost at $10–$13 per unit after rebates. That's a gross margin of 15–45% per unit—wide range because it depends on your rebate tier, patient mix (cash vs. insurance), and whether you're bundling with other services. Example: if you buy Botox at $11/unit (after rebate), inject at $15/unit, and inject 500 units per patient (5 vials), your gross margin per patient is $20 (5 units × $4 margin). Scale that across 100 patients/month and you're looking at $2,000/month gross margin on toxin alone—before overhead. Insurance reimbursement (Medicare, commercial plans) typically pays $8–$12 per unit, which can compress margin to near-zero if your wholesale cost is high. Many practices use cash pricing for toxin to protect margin; insurance is reserved for therapeutic indications (hyperhidrosis, migraine) where reimbursement is more predictable. Track your blended per-unit cost (total annual spend ÷ total units purchased) and compare it to your average injection price to identify margin leakage.

Most practices buy direct from manufacturers (Allergan, Galderma, Evolus) or through group purchasing organizations (GPOs) like Henry Schein One or Medline. Direct buying offers better rebates and co-marketing support but requires higher minimum orders and longer payment terms. GPOs offer convenience and lower minimums but often have higher per-unit cost because the GPO takes a margin. Distributors (e.g., Henry Schein, Medline) are middle-ground: faster delivery, smaller orders, but 5–10% markup over direct pricing. For a practice injecting 1,000+ vials annually, direct buying with Allē or Aspire typically beats GPO pricing by $1–$2/unit. For smaller practices (200–500 vials/year), GPO or distributor convenience may offset the per-unit premium. Calculate your break-even: if direct buying saves $2/unit but requires $5K minimum orders and 30-day payment terms, and you only inject 100 vials/month, the cash-flow hit may not be worth it. Negotiate with your rep; many will match competitor pricing or offer custom rebates to lock in volume.